Welcome to Real Deals' 2023 Healthcare Report, which explores how private equity can be a force for good when it comes to investing in the space in Europe. 

Amid macroeconomic turmoil, healthcare is an island of stability. That is the consensus from most private equity market participants that Real Deals spoke to for this special healthcare report. Despite an overall dip in European private equity deal numbers, certain sub-sectors within healthcare, such as biopharma, continue to perform well and have even seen an uptick in transactions.

But investing in healthcare doesn't come without some risks. GPs deploying in the sector need to be wary of potential regulatory changes, particularly as governments continue to grapple with rising healthcare costs. There is also always a degree of uncertainty when it comes to clinical trials and drug approvals, which can impact the success of investments in biopharma.

Overall though, the healthcare sector remains an attractive option for private equity investors, particularly those that are able to navigate the risks and capitalise on the opportunities within the space. As we continue to navigate these uncertain times, it is reassuring to know that healthcare is a reliable source of stability and growth in the market.

To read the Real Deals Healthcare Report 2023 for free, click here, or access the various features directly via the links below.